一種無痛激光治療方法無需手術(shù)，恢復(fù)時間很短，能夠挽救血流阻塞肢體，免于截肢。

冷激光血管再形成用于外周動脈治療(CLiRpath)是由Spectranetics公司(Colorado Springs, CO, USA)開發(fā)的，使用該公司CVX-300 受激準(zhǔn)分子激光發(fā)射308納米波長“冷” 紫外光，通過纖維-光學(xué)發(fā)射設(shè)備和導(dǎo)管系統(tǒng)來控制能量脈沖，該導(dǎo)管系統(tǒng)由微小的、柔軟的硅纖維制造的，每根直徑只相當(dāng)于一根頭發(fā)。

這種激光能夠精確瞄準(zhǔn)并使得阻塞物氣化，從而恢復(fù)血流，并且不會損傷周圍的動脈。在激光治療之后，在所有患者進(jìn)行氣囊血管重建術(shù)，幫助擴(kuò)張?jiān)?jīng)被阻塞的動脈。手術(shù)能夠促進(jìn)傷口愈合，確保患者在術(shù)后第一天即可出院。CLiRpath已經(jīng)經(jīng)過了嚴(yán)格的臨床試驗(yàn)，在95％的患者保留了肢體并存活至6個月。
Cool Laser Saves Limbs from Amputation
 

 
A painless laser procedure that requires no surgery and minimal recovery time can save limbs with blocked blood flow from amputation.

Cool laser revascularization for peripheral artery therapy (CLiRpath), developed by Spectranetics (Colorado Springs, CO, USA), uses the company’s CVX-300 excimer laser to deliver 308 nanometer wavelength “cool” ultraviolet light in short, controlled energy pulses via fiber-optic delivery devices and a catheter system made of tiny, flexible silica fibers, each about the width of a human hair.

The laser is able to precisely target and vaporize blockages, restoring blood flow without damage to the surrounding artery. After the laser procedure, balloon angioplasty is performed on almost all patients to help open the once-blocked artery. The surgery promotes wound healing, often enabling patients to leave the hospital the next day. CLiRpath has been the subject of rigorous clinical trials, with limb salvage observed in 95% of patients surviving to six months.